CTI BioPharma Corp (NASDAQ:CTIC)(MTA:CTIC) stated on Wednesday that it expects to receive USD10m in milestone payment for TRISENOX from Teva Pharmaceutical Industries Ltd in February 2018.
According to CTI BioPharma Corp, the expected milestone payment is related to the US Food and Drug Administration's approval of TRISENOX (arsenic trioxide) for first line treatment of acute promyelocytic leukemia.
Under the terms of a prior acquisition agreement for TRISENOX with Teva, CTI BioPharma is eligible to receive up to an additional USD50m in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX.
Headquartered in Seattle, Washington, CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval